Bulletin
Investor Alert

Alexion Pharmaceuticals Inc.

NAS: ALXN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 5, 2021, 5:29 p.m.

/zigman2/quotes/206262068/composite

$

150.10

Change

0.00 0.00%

Volume

Volume 89,322

Quotes are delayed by 20 min

/zigman2/quotes/206262068/composite

Previous close

$ 148.46

$ 150.10

Change

+1.64 +1.10%

Day low

Day high

$148.18

$150.56

Open

52 week low

52 week high

$72.67

$162.60

Open

Daniel A. Bazarko

Presently, Daniel A. Bazarko occupies the position of Chief Accounting Officer & Senior Vice President at Alexion Pharmaceuticals, Inc.

Transactions

Date Shares Transaction Value
02/28/2021 7,616   Award at $0 per share. 0
12/17/2020 1,100   Disposition at $158 per share. 173,800
12/17/2020 13,066   Disposition at $157.76 per share. 2,061,293
12/17/2020 9,900   Disposition at $157.59 per share. 1,560,141
12/17/2020 11,000   Derivative/Non-derivative trans. at $140.16 per share. 1,541,760
12/17/2020 13,066   Derivative/Non-derivative trans. at $97.58 per share. 1,274,980
12/16/2020 1,725   Derivative/Non-derivative trans. at $157.96 per share. 272,481
12/16/2020 7,087   Derivative/Non-derivative trans. at $157.96 per share. 1,119,463
12/16/2020 15,371   Award at $0 per share. 0
03/02/2020 886   Derivative/Non-derivative trans. at $90.53 per share. 80,210
02/28/2020 3,927   Award at $0 per share. 0
02/27/2020 216   Derivative/Non-derivative trans. at $92.97 per share. 20,082
02/07/2020 851   Derivative/Non-derivative trans. at $102.97 per share. 87,628
12/02/2019 1,185   Derivative/Non-derivative trans. at $113.2 per share. 134,142
02/28/2019 381   Derivative/Non-derivative trans. at $132.92 per share. 50,643
02/28/2019 3,403   Award at $0 per share. 0
02/28/2019 216   Derivative/Non-derivative trans. at $132.92 per share. 28,711
02/27/2019 70   Derivative/Non-derivative trans. at $135.58 per share. 9,491
02/26/2019 213   Derivative/Non-derivative trans. at $132.49 per share. 28,221
02/14/2019 2,000   Disposition at $126 per share. 252,000

Officers and Executives

Dr. Ludwig N. Hantson
Chief Executive Officer & Director
Dr. Aradhana Sarin
Chief Financial Officer & Executive Vice President
Mr. Brian M. Goff
Chief Commercial, Global Operations Officer & EVP
Mr. George Llado
Chief Information Officer & Senior Vice President
Dr. John J. Orloff
Executive VP, Head-Research & Development
Dr. Tanisha V. Cariño
Chief Corporate Affairs Officer & EVP
Dr. Gianluca Pirozzi
Head-Clinical Development, Hematology & Nephrology
Mr. Uzair Qadeer
Chief Diversity Officer
Ms. Becky Lillie
Chief Human Experience Officer
Ms. Tamar Thompson
Vice President-US Government Affairs & Policy
Ms. Indrani M. Franchini
Chief Compliance Officer & Executive VP
Ms. Rana Strellis
SVP-Global Culture & Social Responsibility
Mr. Daniel A. Bazarko
Chief Accounting Officer & Senior Vice President
Mr. Christopher J. Stevo
Head-Investor Relations1
Ms. Morgan Sanford
Chief of Staff
Ms. Ellen V. Chiniara
Secretary, Chief Legal Officer & Executive VP
Mr. David Richard Brennan
Chairman
Dr. Andreas Rummelt
Independent Director
Mr. John T. Mollen
Independent Director
Mr. Christopher J. Coughlin
Independent Director
Dr. Paul A. Friedman
Independent Director
Dr. Francois Nader
Independent Director
Dr. Deborah L. Dunsire
Independent Director
Ms. Judith A. Reinsdorf
Independent Director
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.